| Xometry, Inc. and Subsidiaries | ||||||||
| Unaudited Condensed Consolidated Statements of Cash Flows | ||||||||
| (In thousands) | ||||||||
| Six Months Ended June 30, | ||||||||
| 2023 | 2022 | |||||||
| Cash flows from operating activities: | (unaudited) | |||||||
| Net loss | $ | (44,902 | ) | $ | (36,544 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation and amortization | 5,461 | 3,807 | ||||||
| Impairment of assets | 246 | 119 | ||||||
| Reduction in carrying amount of right-of-use asset | 12,179 | 3,540 | ||||||
| Stock based compensation | 10,492 | 8,935 | ||||||
| Revaluation of contingent consideration | 187 | 434 | ||||||
| Income from unconsolidated joint venture | (203 | ) | (103 | ) | ||||
| Donation of common stock | 370 | 1,285 | ||||||
| Unrealized loss on marketable securities | — | 1,190 | ||||||
| Non-cash income tax benefit | — | (559 | ) | |||||
| Loss on sale of property and equipment | 92 | 71 | ||||||
| Inventory write-off | 223 | — | ||||||
| Amortization of deferred costs on convertible notes | 930 | 781 | ||||||
| Deferred taxes benefit | (44 | ) | (2 | ) | ||||
| Changes in other assets and liabilities: | ||||||||
| Accounts receivable, net | (8,308 | ) | (11,833 | ) | ||||
| Inventory | 5 | 272 | ||||||
| Prepaid expenses | 1,417 | (1,649 | ) | |||||
| Other assets | (2,546 | ) | (3,861 | ) | ||||
| Accounts payable | (50 | ) | 1,873 | |||||
| Accrued expenses | 2,743 | (2,041 | ) | |||||
| Contract liabilities | 1,470 | 2,862 | ||||||
| Lease liabilities | (2,369 | ) | (2,773 | ) | ||||
| Net cash used in operating activities | (22,607 | ) | (34,196 | ) | ||||
| Cash flows from investing activities: | ||||||||
| Purchases of marketable securities | (5,641 | ) | (280,559 | ) | ||||
| Proceeds from sale of marketable securities | 30,000 | 4 | ||||||
| Purchases of property and equipment | (8,492 | ) | (5,436 | ) | ||||
| Proceeds from sale of property and equipment | 223 | 165 | ||||||
| Cash paid for business combination, net of cash acquired | (3,349 | ) | — | |||||
| Net cash provided by (used in) investing activities | 12,741 | (285,826 | ) | |||||
| Cash flows from financing activities: | ||||||||
| Proceeds from stock options exercised | 1,144 | 2,470 | ||||||
| Proceeds from issuance of convertible notes | — | 287,500 | ||||||
| Costs incurred in connection with issuance of convertible notes | — | (9,309 | ) | |||||
| Payments on finance lease obligations | — | (2 | ) | |||||
| Net cash provided by financing activities | 1,144 | 280,659 | ||||||
| Effect of foreign currency translation on cash and cash equivalents | (202 | ) | (66 | ) | ||||
| Net decrease in cash and cash equivalents | (8,924 | ) | (39,429 | ) | ||||
| Cash and cash equivalents at beginning of the year | 65,662 | 86,262 | ||||||
| Cash and cash equivalents at end of the period | $ | 56,738 | $ | 46,833 | ||||
| Supplemental cash flow information: | ||||||||
| Cash paid for interest | $ | 1,438 | $ | — | ||||
| Non-cash investing and financing activities: | ||||||||
| Non-cash consideration in connection with business combination | 1,593 | — | ||||||
